|
1.
|
|
16 p, 1.2 MB |
A RAD51 assay feasible in routine tumor samples calls inhibitor response beyond BRCA mutation
/
Castroviejo-Bermejo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Cruz Zambrano, Cristina (Universitat Autònoma de Barcelona) ;
Llop-Guevara, Alba (Vall d'Hebron Institut d'Oncologia) ;
Gutiérrez-Enríquez, Sara (Vall d'Hebron Institut d'Oncologia) ;
Ducy, Mandy (CHUL. Genomics Center) ;
Ibrahim, Yasir Hussein (Vall d'Hebron Institut d'Oncologia) ;
Gris-Oliver, Albert (Vall d'Hebron Institut d'Oncologia) ;
Pellegrino, Benedetta (University Hospital of Parma) ;
Bruna, Alejandra (University of Cambridge) ;
Guzmán, Marta (Vall d'Hebron Institut d'Oncologia) ;
Rodríguez, Olga (Vall d'Hebron Institut d'Oncologia) ;
Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ;
Bonache, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Moles-Fernández, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Gómez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Vidal, Marc (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Instituto de Salud Carlos III) ;
Serres-Créixams, Xavier (Hospital Universitari Vall d'Hebron) ;
Dellaire, Graham (Dalhousie University) ;
Simard, Jacques (CHUL. Genomics Center) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rubio, Isabel T. (Hospital Universitari Vall d'Hebron) ;
Dientsmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Barrett, J. Carl (AstraZeneca) ;
Caldas, Carlos (Cancer Research UK (CRUK) Cambridge Cancer Centre) ;
Baselga Torres, Josep 1959-2021 (Memorial Sloan Kettering Cancer Center) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Déas, Olivier (XenTech) ;
Jonkers, Jos (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Masson, Jean-Yves (Laval University Cancer Research Center) ;
Cairo, Stefano (XenTech) ;
Judde, Jean-Gabriel (XenTech) ;
O'Connor, Mark J.. (AstraZeneca) ;
Diez, Orland (Vall d'Hebron Institut d'Oncologia) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
Poly(-ribose) polymerase () inhibitors (i) are effective in cancers with defective homologous recombination repair (), including 1/2-related cancers. A test to identify additional -deficient tumors will help to extend their use in new indications. [...]
2018 -  10.15252/emmm.201809172
EMBO Molecular Medicine, Vol. 10 (october 2018)
|
|
|
2.
|
|
14 p, 1.4 MB |
Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors
/
Pasculli, Barbara (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Barbano, Raffaela (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Fontana, Andrea (Fondazione IRCCS Casa Sollievo Della Sofferenza) ;
Biagini, T. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratory of Bioinformatics Unit) ;
Di Viesti, M. P. (Department of Medicine. Scuola Medica Salernitana," University of Salerno) ;
Rendina, M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Valori, V. M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ;
Morritti, M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ;
Bravaccini, Sara (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Biosciences Laboratory) ;
Ravaioli, S. (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Biosciences Laboratory) ;
Maiello, Evaristo (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ;
Graziano, Paolo (Fondazione IRCCS Casa Sollievo Della Sofferenza) ;
Murgo, R. (Fondazione IRCCS Casa Sollievo Della Sofferenza) ;
Copetti, Massimiliano (Fondazione IRCCS Casa Sollievo Della Sofferenza) ;
Mazza, T. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratory of Bioinformatics Unit) ;
Fazio, V. M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Parrella, Paola (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Universitat Autònoma de Barcelona
miR-155-5p is a well-known oncogenic microRNA, showing frequent overexpression in human malignancies, including breast cancer. Here, we show that high miR-155-5p levels are associated with unfavorable prognostic factors in two independent breast cancer cohorts (CSS cohort, n = 283; and TCGA-BRCA dataset, n = 1,095). [...]
2020 - 10.3389/fonc.2020.01415
Frontiers in Oncology, Vol. 10 (december 2020) , p. 1415
|
|
|
3.
|
|
14 p, 6.4 MB |
ATR is required to complete meiotic recombination in mice
/
Pacheco, Sarai (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Maldonado Linares, Andros (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Marcet-Ortega, Marina (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Rojas, Cristina (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Martínez Marchal, Ana (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Fuentes Lazaro, Judit (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Lange, Julian (Memorial Sloan Kettering Cancer Center) ;
Jasin, Maria (Memorial Sloan Kettering Cancer Center) ;
Keeney, Scott (Memorial Sloan Kettering Cancer Center) ;
Fernández-Capetillo, Oscar (Centro Nacional de Investigaciones Oncológicas) ;
Garcia-Caldés, Montserrat (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Roig, Ignasi (Ignasi) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Precise execution of recombination during meiosis is essential for forming chromosomally-balanced gametes. Meiotic recombination initiates with the formation and resection of DNA double-strand breaks (DSBs). [...]
2018 - 10.1038/s41467-018-04851-z
Nature communications, Vol. 9 (2018) , art. 2622
|
|
|
4.
|
|
11 p, 987.0 KB |
Activation of r20-dependent recombination and horizontal gene transfer in Mycoplasma genitalium
/
Torres Puig, Sergi (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Martínez Torró, Carlos (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Granero Moya, Ignasi (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Querol Murillo, Enrique (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Piñol Ribas, Jaume (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Pich, Òscar M. (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
In the human pathogen Mycoplasma genitalium, homologous recombination is under the control of r, an alternative sigma factor that boosts the generation of genetic and antigenic diversity in the population. [...]
2018 - 10.1093/dnares/dsy011
DNA research, Vol. 25, issue 4 (2018) , p. 383-393
|
|
|
5.
|
|
8 p, 473.7 KB |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
/
Cruz, C. (Vall d'Hebron Institut d'Oncologia) ;
Castroviejo-Bermejo, Marta (Experimental Therapeutics Group) ;
Gutiérrez-Enríquez, Sara (Oncogenetics Group) ;
Llop-Guevara, A. (Experimental Therapeutics Group) ;
Ibrahim, Y. H. (Experimental Therapeutics Group) ;
Gris-Oliver, Albert. (Experimental Therapeutics Group) ;
Bonache, Sandra (Oncogenetics Group) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Bruna, Alejandra (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Rueda, O. M. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Lai, Z. (AstraZeneca (USA)) ;
Polanska, U. M. (Cancer Research UK. Cambridge Institute) ;
Jones, G. N. (Cancer Research UK. Cambridge Institute) ;
Kristel, P. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
de Bustos, L. (Experimental Therapeutics Group) ;
Guzmán, Marta (Experimental Therapeutics Group) ;
Rodríguez, O. (Experimental Therapeutics Group) ;
Grueso, Judit (Experimental Therapeutics Group) ;
Montalban, G. (Oncogenetics Group) ;
Caratù, Ginevra (Cancer Genomics Group) ;
Mancuso, Francesco M (Cancer Genomics Group) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ;
Howat, W. J. (Cancer Research UK. Cambridge Institute) ;
Dougherty, B. (AstraZeneca (USA)) ;
Vivancos, A. (Cancer Genomics Group) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Serres-Créixams, X. (Department of Radiology) ;
Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ;
Oaknin, Ana (Vall d'Hebron Institut d'Oncologia) ;
Cadogan, E. (Cancer Research UK. Cambridge Institute) ;
Barrett, J. Carl (AstraZeneca (USA)) ;
Caldas, Carlos (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ;
Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Jonkers, Jos (Cancer Genomics Group) ;
Diez, Orland (Hospital Universitari Vall d'Hebron) ;
O'Connor, M. J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210
|
|
|
6.
|
|
9 p, 1.0 MB |
Deletions and duplications of the 22q11.2 region in spermatozoa from DiGeorge/velocardiofacial fathers
/
Vergés i Torroella, Laia (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Molina, Òscar (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Geán, Esther (Hospital Sant Joan de Déu (Manresa)) ;
Vidal, Francesca (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Blanco, Joan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Background: DiGeorge/velocardiofacial syndrome (DGS/VCFS) is the most common deletion syndrome in humans. Low copy repeats flanking the 22q11. 2 region confer a substrate for non-allelic homologous recombination (NAHR) events leading to rearrangements. [...]
2014 - 10.1186/s13039-014-0086-3
Molecular Cytogenetics, Vol. 7 (November 2014) , art. 86
|
|
|
7.
|
|
7 p, 1.1 MB |
High-resolution fish on DNA fibers for low-copy repeats genome architecture studies
/
Molina, Òscar (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Blanco, Joan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Anton, Ester (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Vidal, Francesca (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Volpi, E. V. (University of Oxford. The Wellcome Trust Center for Human Genetics)
Low-copy repeats (LCRs) constitute 5% of the human genome. LCRs act as substrates for non-allelic homologous recombination (NAHR) leading to genomic structural variation. The aim of this study was to assess the potential of Fiber-FISH for LCRs direct visualization to support investigations of genome architecture within these challenging genomic regions. [...]
2012 - 10.1016/j.ygeno.2012.08.007
Genomics, Vol. 100, Num. 6 (December 2012) , p. 380-386
|
|
|
8.
|
|
21 p, 3.9 MB |
Transcriptomic and proteomic profiling of maize embryos exposed to camptothecin
/
Sánchez-Pons, Nuria (Centre de Recerca en Agrigenòmica) ;
Irar, Sami (Centre de Recerca en Agrigenòmica) ;
García-Muniz, Nora (Centre de Recerca en Agrigenòmica) ;
Vicient Sánchez, Carlos M. (Centre de Recerca en Agrigenòmica)
Camptothecin is a plant alkaloid that specifically binds topoisomerase I, inhibiting its activity and inducing double stranded breaks in DNA, activating the cell responses to DNA damage and, in response to severe treatments, triggering cell death. [...]
2011 - 10.1186/1471-2229-11-91
BMC plant biology, Vol. 11 (May 2011) , art. 91
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
